The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06151288
Recruitment Status : Active, not recruiting
First Posted : November 30, 2023
Last Update Posted : January 30, 2024
Sponsor:
Information provided by (Responsible Party):
Vaxcyte, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The objective of the study is to evaluate the safety, tolerability and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 50 to 64 years of age in Stage 1. Stage 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-31 at 3 dose levels compared to PCV20 in adults aged 50 years and older.

Condition or disease Intervention/treatment Phase
Pneumococcal Vaccines Biological: 31 valent pneumococcal conjugate vaccine Biological: 20 valent pneumococcal conjugate vaccine Phase 1 Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1015 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Active-Controlled, Parallel-Group, Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Healthy Adults Aged 50 Years and Older
Actual Study Start Date : November 8, 2023
Estimated Primary Completion Date : September 2024
Estimated Study Completion Date : September 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vaccines

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Group 1
Participants will receive a single low dose of VAX-31 administered as an intramuscular injection at Day 1.
 Biological: 31 valent pneumococcal conjugate vaccine
0.5 ml dose of VAX-31 will be administered into the deltoid muscle at Day 1
Experimental: Group 2
Participants will receive a single mid dose of VAX-31 administered as an intramuscular injection at Day 1.
 Biological: 31 valent pneumococcal conjugate vaccine
0.5 ml dose of VAX-31 will be administered into the deltoid muscle at Day 1
Experimental: Group 3
Participants will receive a single high dose of VAX-31 administered as an intramuscular injection at Day 1.
 Biological: 31 valent pneumococcal conjugate vaccine
0.5 ml dose of VAX-31 will be administered into the deltoid muscle at Day 1
Active Comparator: Group 4
Participants will receive a single intramuscular injection of the standard dose of PCV20 at Day 1.
 Biological: 20 valent pneumococcal conjugate vaccine
0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1
Other Names:
  • PCV20
  • Prevnar 20™


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percentage of participants reporting solicited local reactions within 7 days after vaccination (redness, swelling, and pain at injection site) in each age group [ Time Frame: 7 days after vaccination ]
  2. Percentage of subjects reporting solicited systemic events within 7 days after vaccination (fever, headache, fatigue, muscle pain, and joint pain) in each age group vaccination in each age group [ Time Frame: 7 days after vaccination ]
  3. Percentage of subjects reporting unsolicited Adverse Event in each age group [ Time Frame: 1 month after vaccination ]
  4. Percentage of subjects reporting Serious Adverse Event [ Time Frame: 6 months after vaccination ]
  5. Percentage of subjects reporting New Onset of Chronic Illness [ Time Frame: 6 months after vaccination ]
  6. Percentage of subjects reporting Medically Attended Adverse Event [ Time Frame: 6 months after vaccination ]

Secondary Outcome Measures :
  1. Percentage of participants with Adverse Events due to clinically significant laboratory values [ Time Frame: 1 month after vaccination ]
  2. Percentage of participants with a shift from normal at baseline to abnormal at post-vaccination in safety laboratory parameters (hematology, clinical chemistry, urinalysis) [ Time Frame: 1 month after vaccination ]
  3. 31 VAX-31 Pneumococcal serotype-specific OPA geometric mean titer [ Time Frame: 1 month after vaccination ]
  4. 31 VAX-31 Pneumococcal serotype-specific IgG geometric mean concentration [ Time Frame: 1 month after vaccination ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female aged 50 to 64 years (inclusive) for Stage 1, or 50 years and older (inclusive) for Stage 2 at the time of randomization into the study.
  2. Able and willing to complete the informed consent process.
  3. Available for clinical follow-up through the last study visit at 6 months after the study vaccination.
  4. In good general health as determined by medical history, vital signs, physical examination, and clinical judgment of the Investigator.
  5. Willing to have blood samples collected, stored indefinitely, and used for research purposes.
  6. Able to provide proof of identity to the satisfaction of the study staff completing the enrollment process.
  7. Women of childbearing potential, defined as premenopausal females capable of becoming pregnant, must have a negative urine pregnancy test immediately prior to randomization and agree to use acceptable contraception
  8. Able to access and use a smartphone, tablet, computer, or other device connected to Wi-Fi or cellular network for completion of an electronic diary.

Exclusion Criteria:

  1. Previous pneumococcal disease (either confirmed or self-reported).
  2. Previous receipt of a licensed or investigational pneumococcal vaccine.
  3. Receipt of any investigational study product within 30 days prior to enrollment into the study, currently participating in another interventional investigational study, or having plans to receive another investigational product(s) while on study.
  4. Planned or actual administration of any licensed vaccine during the period starting 30 days before enrollment into the study through Month 1.
  5. Physical examination indicating any clinically significant medical condition.
  6. Body Temperature >38.0°C (>100.4°F) or acute illness within 3 days prior to study vaccination (subject may be rescheduled).
  7. Previous or existing diagnosis of HIV, Hepatitis B, or Hepatitis C.
  8. History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis.
  9. Female who is pregnant, breastfeeding, or planning to become pregnant during study participation.
  10. Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) resulting in clinically significant bruising or bleeding difficulties with IM injections or blood draws.
  11. Any other chronic or clinically significant medical condition that, in the opinion of the Investigator, would jeopardize the safety or rights of the subject or confound evaluation of the study vaccine.
  12. Any medical, psychiatric, or social condition that in the judgment of the Investigator is a contraindication to protocol participation or impairs a subject's ability to give informed consent.
  13. Received blood or blood product (including Immune Globulin IV) within 90 days prior to enrollment into the study.

  14. Received systemic corticosteroids (except for inhaled, topical, intra-articular) for

    ≥14 consecutive days and has not completed treatment ≤30 days prior to enrollment into the study.

  15. Receiving immunosuppressive therapy.
  16. History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06151288


Locations
Show Show 25 study locations
Sponsors and Collaborators
Vaxcyte, Inc.
Investigators
Layout table for investigator information
Study Director: Clinical Development Vaxcyte, Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Vaxcyte, Inc.
ClinicalTrials.gov Identifier: NCT06151288    
Other Study ID Numbers: VAX31-101
First Posted: November 30, 2023    Key Record Dates
Last Update Posted: January 30, 2024
Last Verified: January 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Vaccines
Heptavalent Pneumococcal Conjugate Vaccine
Immunologic Factors
Physiological Effects of Drugs